Lithium-responsive intracellular pathways in the central nervous system

Lithium-responsive intracellular pathways in the central nervous system (CNS) represent a multifaceted network of signaling cascades that mediate the therapeutic effects of lithium, primarily in the treatment of bipolar disorder (nih.gov, 2015). These pathways are centered around two key molecular targets: glycogen synthase kinase-3 (GSK-3) and inositol monophosphatase (IMPA), both of which are inhibited by lithium through the displacement of magnesium ions (droracle.ai, 2026; youtube.com, 2015). The inhibition of IMPA supports the inositol depletion hypothesis, which suggests that reducing inositol levels dampens overactive phosphoinositide signaling associated with mania (nih.gov, 2015). Simultaneously, the inhibition of GSK-3 promotes neuroprotective and neuroplastic effects by activating the Wnt/beta-catenin pathway and upregulating brain-derived neurotrophic factor (BDNF) (droracle.ai, 2025; nih.gov, 2023). Beyond these primary targets, lithium modulates protein kinase C (PKC) activity, calcium homeostasis, and the phosphorylation of collapsin response mediator protein-2 (CRMP2), which is linked to dendritic spine stability (pnas.org, 2017). These diverse actions collectively enhance cellular resilience and stabilize neuronal circuits, though they also account for lithium's narrow therapeutic window and systemic side effects like renal and thyroid dysfunction (youtube.com, 2022; researchgate.net, 2014).

Other names

Lithium signaling pathwaysLithium-sensitive pathwaysInositol depletion pathwayGSK-3 signaling pathwayLithium response pathway

Lithium acts by inhibiting key enzymes such as glycogen synthase kinase-3 (GSK-3) and inositol monophosphatase (IMPA), which leads to the depletion of intracellular inositol and the modulation of downstream signaling pathways including Wnt/beta-catenin and BDNF-mediated neuroprotection (nih.gov, 2015; droracle.ai, 2026).